AMBS Stock UPDATES Amarantus Biosci Inc (AMBS) 0.1140 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amarantus Biosci Inc (AMBS) 0.1140 $AMBS

Amarantus to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Aug 19, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO, is scheduled to present to investors at the 16th Annual Rodman & Renshaw Healthcare Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City. The presentation is scheduled for Tuesday, September 9th at 2:30 PM ET and will be web cast live, please visit the Company's IR Events section to participate. Additional information about the conference can be found at http://www.rodm.com/.

Amarantus announces exercise of option to license intellectual property from University of Miami Bascom Palmer Eye Institute for retinal disorders
M2 - Mon Aug 18, 6:39AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) reported on Friday that it has exercised its exclusive perpetual option to license intellectual property related to MANF's utility in treating retinal disorders from the University of Miami's Bascom Palmer Eye Institute.

Amarantus Exercises Option to License Intellectual Property From University of Miami Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
GlobeNewswire - Fri Aug 15, 7:10AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced that it exercised its exclusive option to license intellectual property related to MANF's utility in treating retinal disorders from the University of Miami's Bascom Palmer Eye Institute, and has entered into an exclusive license for said intellectual property. Under the terms of the agreement, the Company has been granted a perpetual, exclusive worldwide license to intellectual property, covering the use of MANF for the treatment of retinal disorders, including Retinitis pigmentosa.

Amarantus BioScience Holdings, Inc. "Preparing Amarantus for the Up-list in 2H-14: Capital Markets Strategy"
ACCESSWIRE - Mon Aug 11, 7:03AM CDT
New York, NY / ACCESSWIRE / August 11, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, co-written by the Company's CEO, Mr. Gerald Commissiong and Chief Financial Officer, Mr. Robert Farrell, JD. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Amarantus Enters Into Research Collaboration With the Buck Institute for Research on Aging for MANF
GlobeNewswire - Mon Aug 11, 7:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced it has entered into a Research Collaboration with theBuck Institute for Research on Aging for the development of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) in undisclosed therapeutic indications. MANF is a targeted therapeutic which addresses the underlying programmed cell death (apoptosis) associated with a wide range of devastating human disorders including orphan indications such as Retinitis Pigmentosa.

OTC Trading Stock News: Amarantus Biosciences Holdings, Inc. Virtus Oil and Gas Corp, Cannabis Sativa, Inc. Creative Edge Nutrition, Inc. DNA Brands, Inc.
PR Newswire Europe - Tue Aug 05, 7:03AM CDT
LONDON, August 5, 2014 /PRNewswire/ --

Amarantus BioScience Holdings, Inc. - "#C4CT Wrap-up and the Decision to Present Interim LP-002 Data"
ACCESSWIRE - Mon Aug 04, 3:26PM CDT
New York, NY / August 4, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

#C4CT Summit Explored Emerging Theories on Traumatic Brain Injury, Chronic Traumatic Encephalopathy and Possible Links to Alzheimer's Disease
GlobeNewswire - Mon Aug 04, 7:04AM CDT
Brewer Sports International (BSI), a multi-faceted global advisory firm, andAmarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today reported that a cross-section of researchers, clinicians, policy-makers, patient groups and athletes presented at the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY.

Cerora, Inc. Announces Second Close in Seed Round of Financing
ACCESSWIRE - Fri Aug 01, 10:15AM CDT
Supports Proprietary 'Near the Field' Objective Concussion Evaluation Technology

Amarantus Announces Positive Top-Line Interim Clinical Data for Alzheimer's Blood Diagnostic LymPro Test(R)
GlobeNewswire - Fri Aug 01, 8:25AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive interim clinical performance data for the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test(R), currently under development for Alzheimer's disease diagnosis. In an interim analysis of 44 subjects (34 healthy controls and 10 Alzheimer's patients) from LP-002, a projected 72 patient clinical performance study, the Company announced it achieved replication of the two earlier peer reviewed publications, the primary objective of the study.

Amarantus Acquires Exclusive Option to License Alzheimer's Therapeutic IP of Dr. Thomas Arendt From University of Leipzig
GlobeNewswire - Fri Aug 01, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has acquired an exclusive option to license the intellectual property surrounding the therapeutic concepts of Dr. Thomas Arendt from the University of Leipzig that were presented at the 3 Alzheimer's focused Coalition for Concussion Treatment Summit. Under the terms of the agreement, the Company and the University of Leipzig will have 12 months to negotiate a definitive license agreement, and the Company will work with Dr. Arendt to establish a Sponsored Research Agreement to outline the advancement of the therapeutic strategies into human clinical development.

The 3rd Alzheimer's-Focused #C4CT Concussion Summit Convenes Today at the United Nations
GlobeNewswire - Thu Jul 31, 9:48AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, will be hosting the 3 Alzheimer's-Focused #C4CT Summit powered by MDM Worldwide at the United Nations today.

Registration for the 3rd Alzheimer's-Focused #C4CT Summit Has Closed Due to Overwhelming Interest
GlobeNewswire - Wed Jul 30, 7:06AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced that due to overwhelming registration for the upcoming #C4CT Summit to be held at the United Nations on July 31, 2014, the Coalition for Concussion Treatment is reluctantly unable to accept any new registrants. This summit will be the largest to date with hundreds of confirmed guests including doctors and medical researchers specializing in the treatment of neurodegenerative diseases, policy makers, international ambassadors, athletes and victims of traumatic brain injury (TBI). The summit will cover Alzheimer's disease and other neurodegenerative diseases and the emerging link between traumatic brain injury and neurological conditions.

Amarantus Amends LymPro LP-002 Clinical Protocol to Report Interim Data at #C4CT Presentation
GlobeNewswire - Wed Jul 30, 7:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has amended the clinical protocol for its LP-002 Alzheimer's disease bridging diagnostic study of LymPro in order to perform an interim analysis of 44 subjects recruited from a single clinical site, from an originally planned 72 subjects across 4 clinical sites. The Company intends to report full results upon completion of study enrollment from the three additional clinical sites in the 3 quarter. The Company remains on track to achieve its strategic objectives for LymPro in the 2 half of 2014.

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/djdwhf/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Avineuro Pharmaceuticals, Inc. - Novartis AG - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Pfizer Inc. - Suven Life Sciences Ltd. - Mithridion, Inc. - CoMentis, Inc. - Upsher-Smith Laboratories, Inc. - Siena Biotech S.p.A. - Dart NeuroScience LLC - Intra-Cellular Therapies, Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - SK Biopharmaceuticals Co., Ltd. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/djdwhf/cognitive

Sidney Rice and Ben Utecht Talk to NFL Network's Andrea Kremer and ESPN's Andrew Brandt at Upcoming #C4CT Concussion Awareness Summit at the United Nations
GlobeNewswire - Mon Jul 28, 2:16PM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, are pleased to provide an update surrounding the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY.

Amarantus Appoints Donald D. Huffman to Board of Directors
GlobeNewswire - Mon Jul 28, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced the appointment of Donald D. Huffman to the Company's Board of Directors, where he will chair the newly-formed audit committee. Mr. Huffman brings over 20 years of biopharmaceutical industry experience in various financial and audit roles, with specific expertise in mergers and acquisitions.

Amarantus and BSI Announce Dr. Thomas Arendt as Presenter at 3rd Alzheimer's Focused #C4CT Concussion Awareness Summit at United Nations
GlobeNewswire - Wed Jul 23, 10:34AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced a presentation by Dr. Thomas Arendt, Professor at University of Leipzig, at the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY. Dr. Arendt will summarize his scientific hypotheses regarding the evolutional context of Alzheimer's disease, and an emerging therapeutic target in a 30 minute presentation in the afternoon session.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 161

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 127

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 58

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 118

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 147

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 89

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 142

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 222

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
Nord Anglia Schools Shine with 13 Tes Awards Nominations

Updated Category News Views 154

Nord Anglia's Moment of Glory at Tes Awards You think you know the big players in the educational game? Well, guess again. Nord Anglia's come out swinging with a whopping 13 finalist nominations at the 2026 Tes Awards for International Schools. It ain't easy making waves in the education sector, but these folks are showing they've got what it takes to turn heads, not just...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 113

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Insights: S&P 500 Forecasted Decline and Job Growth Impact

Updated Category News Views 107

Market Insights on Economic Factors Impacting S&P 500 Recent reports have revealed that the job market in the United States is displaying significant strength. According to recent statistics, there was an addition of 256,000 jobs, which paints a picture of a robust economy. However, this strong job growth can bring mixed signals for investors regarding the stock market,...

Continue Reading
Safety Tech in Fleets: Drivers Embrace Its Role

Updated Category News Views 65

Drivers Warming Up to Fleet Safety Tech Seems like most fleet drivers these days are eyeing safety tech through a fresher lens. Gone are the days when grumbling about privacy was the anthem of the disgruntled. The latest Linxup survey claims a whopping 77% of commercial fleet pros have hopped onto the safety train, happily trading privacy qualms for the perks of solid...

Continue Reading
Celebrating 50 Years of Excellence at Amerijet Airlines

Updated Category News Views 200

Amerijet International Airlines: A Milestone Celebration Amerijet International Airlines proudly celebrates its 50th anniversary this year, marking five decades of dedication to air cargo services that connect diverse regions. Founded by David Bassett in 1974, the airline began its journey as a small Part 135 air-taxi operator, operating a single leased aircraft. Over the...

Continue Reading
Petit Pot Wins $100K Prize at 2024 Real California Milk Event

Updated Category News Views 195

Petit Pot Celebrates a Momentous Achievement in Dairy Innovation In an exciting showcase of dairy innovation, Petit Pot has emerged as the grand prize winner of the 2024 Real California Milk (RCM) Excelerator competition. This prestigious award highlights the company's commitment to producing high-quality dairy-based desserts and its remarkable sales achievements in a...

Continue Reading
Exploring the Affordability and Safety Debate in Autos

Updated Category News Views 295

Affordability Angst, and a Scapegoat Nobody Asked For Echoes of old policy fights come roaring back here—every time car prices spike, somebody points at safety rules like they’re the boogeyman under the bed (and, yeah, it kinda ticks me off). Lawmakers have been poking at features like Auto Emergency Braking, and the broader affordability debate has gotten tangled up...

Continue Reading